As China's leading pharmaceutical drug R&D and development company, Hua Medicine announced today that with the help of the BioBay Venture Capital Forum co-sponsored by ChinaBio® LLC and Suzhou BioBay, the company has received a group of US and Chinese famous medical investment companies worth US$50 million. Financing commitment. These investment companies include ARCH Venture Capital Partners, Fidelity Life Sciences, Fidelity Asia Ventures, Venrock, Sino-Alliance International Ltd and Emerging Investment Company Wuxi Yaoming Kangda Venture Capital. These funds will be used to promote the internal R&D of Sinopharm. Projects and financial support for the acquisition, development and development of other projects.
Wuxi PharmaTech's chief financial officer Edward said that the establishment of the Wuxi Venture Fund is mainly to provide financial support for companies like Hua Medicine. The elite leaders of these companies will create technologies and products through various effective cooperation and commercialization. Change. The elite drug research and development team owned by Hua Medicine has the ability to carry out multiple projects at the same time, from early R&D projects to obtaining project approvals so that products can be successfully commercialized in China.
China Pharmaceutical Board member and Fidelity's Asian venture capital management partner Daniel Orrbach said: "Unlike most new biotech companies that take ten years or more to benefit, Hua Medicine can use its R&D, management and development. Professional resources have created considerable short-term value from a series of mature projects. We are very pleased that Hua Medicine has such opportunities. The company is currently discussing with multiple municipalities to build more infrastructure for our projects locally."
China Pharmaceutical CEO Chen Li added: “Huazhong Pharmaceuticals is committed to establishing a better new method, combining the advantages of East and West, developing new drugs and commercializing them.
. I have the privilege of forging a strong team that includes some well-known medical investment companies, such as new corporate investors - Wuxi WuXing Kangda, a leading company in China's life sciences.
The founders of China Pharmaceuticals include Dr. Chen Li, former Chief Scientific Officer of Roche Research and Development Center; discoverer of Jack Baldwin-Merk-Trusopt; and co-founder and Scientific Director of Pharmacopeia and Vitae Pharmaceutica LS; John Cai--from Venrock; Dr. Ge - Founder, President and CEO of Wuxi Yaoming Kangda; Daniel Orr Bach - Fidelity Asia FidelAsia Venture Capital Management Partner; Brian Robert - Founder of Venroc and Robert Nielsen - ARCH Venture Partners And managing director.
About Chinese medicine
Hua Medicine is committed to becoming a first-class fully integrated biotechnology company with a focus on the world market. The company makes full use of China's low-cost but high-quality drug discovery capabilities and collaborates with and authorizes licensing deals with highly promising drug resources in Asia, the United States, and Europe. Through these efforts, Hua Medicine is determined to become the driving force for China to become an international drug research and innovation center.
About BioBay Venture Capital Forum
The fourth annual BioBay Venture Investment Forum was held in Suzhou, China. 19 early life science companies presented project roadshows to more than 50 investment companies at the meeting. The conference was jointly organized by ChinaBio® LLC, a consulting and conference organiser in Shanghai, and Suzhou Industrial Park, China’s fastest growing life science park.
Wuxi PharmaTech's chief financial officer Edward said that the establishment of the Wuxi Venture Fund is mainly to provide financial support for companies like Hua Medicine. The elite leaders of these companies will create technologies and products through various effective cooperation and commercialization. Change. The elite drug research and development team owned by Hua Medicine has the ability to carry out multiple projects at the same time, from early R&D projects to obtaining project approvals so that products can be successfully commercialized in China.
China Pharmaceutical Board member and Fidelity's Asian venture capital management partner Daniel Orrbach said: "Unlike most new biotech companies that take ten years or more to benefit, Hua Medicine can use its R&D, management and development. Professional resources have created considerable short-term value from a series of mature projects. We are very pleased that Hua Medicine has such opportunities. The company is currently discussing with multiple municipalities to build more infrastructure for our projects locally."
China Pharmaceutical CEO Chen Li added: “Huazhong Pharmaceuticals is committed to establishing a better new method, combining the advantages of East and West, developing new drugs and commercializing them.
. I have the privilege of forging a strong team that includes some well-known medical investment companies, such as new corporate investors - Wuxi WuXing Kangda, a leading company in China's life sciences.
The founders of China Pharmaceuticals include Dr. Chen Li, former Chief Scientific Officer of Roche Research and Development Center; discoverer of Jack Baldwin-Merk-Trusopt; and co-founder and Scientific Director of Pharmacopeia and Vitae Pharmaceutica LS; John Cai--from Venrock; Dr. Ge - Founder, President and CEO of Wuxi Yaoming Kangda; Daniel Orr Bach - Fidelity Asia FidelAsia Venture Capital Management Partner; Brian Robert - Founder of Venroc and Robert Nielsen - ARCH Venture Partners And managing director.
About Chinese medicine
Hua Medicine is committed to becoming a first-class fully integrated biotechnology company with a focus on the world market. The company makes full use of China's low-cost but high-quality drug discovery capabilities and collaborates with and authorizes licensing deals with highly promising drug resources in Asia, the United States, and Europe. Through these efforts, Hua Medicine is determined to become the driving force for China to become an international drug research and innovation center.
About BioBay Venture Capital Forum
The fourth annual BioBay Venture Investment Forum was held in Suzhou, China. 19 early life science companies presented project roadshows to more than 50 investment companies at the meeting. The conference was jointly organized by ChinaBio® LLC, a consulting and conference organiser in Shanghai, and Suzhou Industrial Park, China’s fastest growing life science park.
Fd Apple,Freeze Dried Apple Flakes,Freeze Dried Apple,Freeze Dried Apple Granules
Xinghua Dongbao Foods Co.,Ltd , https://www.xhdongbaofoods.com